Patrizia Vici

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 729 citations · Full text

Medicine, Oncology, Pharmacology +17

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

Daniele Marinelli, Marco Mazzotta, Stefano Scalera et al. · Annals of Oncology · 2020 · 223 citations · Full text

Medicine, Molecular Biology, Oncology +16

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

Vincenzo Graziano, Antonino Grassadonia, Laura Iezzi et al. · The Breast · 2019 · 175 citations · Full text

Medicine, Immunology, Oncology +13

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

M López, Patrizia Vici, K Di Lauro et al. · Journal of Clinical Oncology · 1998 · 138 citations

Medicine, Oncology, Pharmacology +16

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

Andrea Botticelli, Concetta Elisa Onesti, Ilaria Grazia Zizzari et al. · Oncotarget · 2017 · 113 citations · Full text

Life Sciences, Immunology, Oncology +13